Tuesday, June 26, 2012

Biosimilars on the move in Asia

While the United States waits on the ruling of the healthcare act tomorrow, including the fate of Biosimilars in the US, from the Supreme Court tomorrow, many countries in Asia Pacific have are embracing the opportunity of biosimilars in their market.  Many of the countries in Asia Pacific have embraced this more cost effective form of treatment for their growing middle class, who often pays for health insurance out of their pockets.  Countries like China, India and Korea lead the way  in manufacturing and others including Japan, Australia, Singapore and Malaysia have regulations according to Pharma Phorum.  While many of these biosimilars companies have no experience in regulated markets, they are developing and distributing biosimilars to semi-regulated.  This gives them immense amounts of knowledge of the drugs, as the Asian biosimilars market accounts for 25% of the worldwide market.

This September in Shanghai at the Partnerships in Clinical Trials Asia conference,  Sandeep Athalye, Vice President and Head of Clinical Development, Biocon will be on hand to present Clinical Strategies to Expedite Development of Biosimilars.  The session will look at the partnerships and benefits and risks of expanding in the current biosimilars market.  For more information on this session and the rest of the event, download the agenda here.  As a reader of this blog, when you   register with code XP1775BLOG and save 15% off the standard rate.

What are the benefits of the companies operating in the semi-regulated markets to their business when they decide to expand in to a regulated market, such as the United States or Europe?

This blog is co-posted with the Future of Biopharma blog.




No comments: